SCHEMBL6280928

SCHEMBL6280928

CC(C)c1ccc(C(=O)Cc2ccncc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
CYP19A1 P11511 2/20 0.46
RAB9A P51151 6/20 0.46
NPC1 O15118 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
MPI P34949 1/20 0.43
FLT1 P17948 2/20 0.42
KDR P35968 2/20 0.42
CNR2 P34972 1/20 0.42
CYP2C9 P11712 1/20 0.41
RXRA P19793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29985938 0.88 USP5 (0.59) USP5MAPTALDH1A1MEN1KMT2A
SCHEMBL17129401 0.87 RXRA (0.64) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6203734 0.82 ALDH1A1 (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6282520 0.81 CYP19A1 (0.42) MAPTALDH1A1LMNAHTTCYP19A1
SCHEMBL17129352 0.81 RAB9A (0.67) USP5MAPTMEN1KMT2ARAB9A
SCHEMBL2512740 0.81 RAB9A (0.64) MEN1KMT2AHTTRAB9ANPC1
SCHEMBL4102938 0.81 L3MBTL1 (0.68) MAPTMEN1KMT2ALMNARAB9A
SCHEMBL6283084 0.79 RAB9A (0.56) MAPTALDH1A1KMT2ALMNAHTT
SCHEMBL3917034 0.79 NPC1 (0.56) USP5MAPTALDH1A1RAB9ANPC1
SCHEMBL6775249 0.79 NPC1 (0.62) MAPTALDH1A1RAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962933-B1 Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-08 US disclosed
US-20040097555-A1 Concomitant drugs TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-20 US disclosed
EP-1402900-A1 MEDICINAL COMPOSITIONS Takeda Chemical Industries, Ltd. (JP) 2004-03-31 EP disclosed
EP-1027050-B1 1,3-THIAZOLES AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ALLERGY, ASTHMA AND DIABETES TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-01-14 EP disclosed
EP-1354603-A1 CONCOMITANT DRUGS Takeda Chemical Industries, Ltd. (JP) 2003-10-22 EP disclosed
US-6620825-B1 1,3-Azole compound substituted by pyridyl; administering as antiasthmatic, antiinflammatory or antiallergen agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-16 US disclosed
US-6436966-B1 Adenosine A3 receptor antagonists TAKEDA CHEMICAL IND., LTD. (JP) 2002-08-20 US disclosed
EP-1205478-A1 p38MAP KINASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2002-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097555-A1 Concomitant drugs TNF, CHUK, CNKSR1 USP5 3482/4885MAPT 2113/4885ALDH1A1 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.